Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
Fleeman N, Houten R, Nevitt S, Mahon J, Beale S, Boland A, Greenhalgh J, Edwards K, Maden M, Bhattacharyya D, Chaplin M, McEntee J, Chow S, Waddell T.
Fleeman N, et al. Among authors: greenhalgh j.
Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238.
Health Technol Assess. 2024.
PMID: 39252678
Free PMC article.